1. Home
  2. HBIO vs MRKR Comparison

HBIO vs MRKR Comparison

Compare HBIO & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harvard Bioscience Inc.

HBIO

Harvard Bioscience Inc.

HOLD

Current Price

$5.11

Market Cap

25.7M

Sector

Industrials

ML Signal

HOLD

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.41

Market Cap

23.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HBIO
MRKR
Founded
1901
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.7M
23.0M
IPO Year
2000
2010

Fundamental Metrics

Financial Performance
Metric
HBIO
MRKR
Price
$5.11
$1.41
Analyst Decision
Buy
Strong Buy
Analyst Count
3
2
Target Price
$15.30
$11.25
AVG Volume (30 Days)
327.0K
121.4K
Earning Date
06-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,176,000.00
N/A
Revenue This Year
$9.13
N/A
Revenue Next Year
$4.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$0.81
52 Week High
$0.95
$4.07

Technical Indicators

Market Signals
Indicator
HBIO
MRKR
Relative Strength Index (RSI) 96.73 45.93
Support Level $0.46 $1.36
Resistance Level N/A $1.44
Average True Range (ATR) 0.10 0.11
MACD 0.28 -0.00
Stochastic Oscillator 95.68 24.70

Price Performance

Historical Comparison
HBIO
MRKR

About HBIO Harvard Bioscience Inc.

Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Share on Social Networks: